LTRNLantern Pharma Inc
LTRN
Lantern Pharma Inc1,533
Mkt Cap
$39.57MVolume
450,890.0052W High
$5.7452W Low
$1.11PE Ratio
-2.42LTRN Fundamentals
Price
$3.50Prev Close
$3.32Open
$3.3850D MA
$2.28Beta
1.90Avg. Volume
383,200.37EPS (Annual)
-$1.57P/B
11.43Rev/Employee
$0.00$22.98
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, today announced that it has received a successful response to its recent Type C meeting request from the...
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational...
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and...
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and...
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company developing targeted and transformative cancer therapies using its proprietary AI and machine learning...
Lantern Pharma Unveils Roadmap for withZeta.ai Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm and ZetaOmics
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, today unveiled the next phase of its development roadmap for withZeta.ai, the companys multi-agentic A.I...
Lantern Pharmas predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company advancing precision oncology through its proprietary RADR AI platform, today announced the expansion of predictBBB.ai into a...
Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut
Lantern Pharma Inc. (NASDAQ: LTRN) (Lantern or the Company), an AI-driven clinical-stage precision oncology company, today announced the first public demonstration of withZeta.ai, its multi-agentic...
Emerging Data for Lantern Pharmas Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure With No Added Toxicity
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) for mid-May 2026 to...
Lantern Pharma Launches withZeta.ai the Worlds First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
Lantern Pharma Inc. (Nasdaq: LTRN) (Lantern or the Company), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai the worlds first and most comprehensive...
<
1
2
...
>
Compact View
Not available
Not available
Advertisement|Remove ads.
Latest LTRN News
ViewLantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
Advertisement|Remove ads.